- Home
- PTN vs CVKD Comparison
PTN vs CVKD Comparison
Compare PTN & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTN
- CVKD
- Stock Information
- Founded
- PTN 1986
- CVKD 2022
- Country
- PTN United States
- CVKD United States
- Employees
- PTN N/A
- CVKD N/A
- Industry
- PTN Biotechnology: Pharmaceutical Preparations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- PTN Health Care
- CVKD Health Care
- Exchange
- PTN Nasdaq
- CVKD Nasdaq
- Market Cap
- PTN 25.4M
- CVKD 20.8M
- IPO Year
- PTN 1993
- CVKD 2023
- Fundamental
- Price
- PTN $1.06
- CVKD $17.40
- Analyst Decision
- PTN Strong Buy
- CVKD Strong Buy
- Analyst Count
- PTN 1
- CVKD 1
- Target Price
- PTN $17.00
- CVKD $32.00
- AVG Volume (30 Days)
- PTN 570.9K
- CVKD 69.6K
- Earning Date
- PTN 02-13-2025
- CVKD 03-10-2025
- Dividend Yield
- PTN N/A
- CVKD N/A
- EPS Growth
- PTN N/A
- CVKD N/A
- EPS
- PTN N/A
- CVKD N/A
- Revenue
- PTN $2,384,113.00
- CVKD N/A
- Revenue This Year
- PTN N/A
- CVKD N/A
- Revenue Next Year
- PTN N/A
- CVKD N/A
- P/E Ratio
- PTN N/A
- CVKD N/A
- Revenue Growth
- PTN N/A
- CVKD N/A
- 52 Week Low
- PTN $0.68
- CVKD $5.40
- 52 Week High
- PTN $5.65
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- PTN 47.60
- CVKD 58.52
- Support Level
- PTN $1.06
- CVKD $15.56
- Resistance Level
- PTN $1.20
- CVKD $18.50
- Average True Range (ATR)
- PTN 0.14
- CVKD 1.43
- MACD
- PTN -0.01
- CVKD 0.19
- Stochastic Oscillator
- PTN 7.14
- CVKD 74.33
About PTN Palatin Technologies Inc.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.